Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03683394 · ClinicalTrials.gov registry record · NA
Systematic Multi-domain Alzheimer's Risk Reduction Trial
A NA study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- NA
- Development phase
- 172
- Enrollment target
NCT03683394: Completed NA study, sponsored by Kaiser Permanente.
NCT03683394 is a NA study that has completed, run by Kaiser Permanente. The registered enrollment target is 172 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03683394, a NA study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- NA
- Development phase
- 172 participants
- Enrollment target
Study Summary
The primary goal of this randomized controlled trial (RCT) is to pilot-test a personalized, pragmatic, multi-domain Alzheimer's disease risk reduction intervention in a U.S. integrated healthcare delivery system.
Primary Outcome
Cognitive function will be measured by the modified Neuropsychological Test Battery (mNTB) global score, which is a composite z-score, an average of z-scores from tests of several cognitive domains. The total score is reported. Higher values signify higher cognitive performance. A z-score of 0 represents the population mean. Treatment effects were estimated using linear mixed models (LMMs) for the changes from baseline to each follow-up assessment (6, 12, 18, and 24 months), with average treatm
Interventions
- BEHAVIORAL Health Education Intervention
- BEHAVIORAL SMARRT Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2018-08-30 |
| Est. Completion | 2022-08-10 |
| Phase | NA |
What the finished NCT03683394 record still lists
NCT03683394 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Health Education Intervention is the first listed.
NCT03683394 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03683394 about?
NCT03683394 is a clinical study titled "Systematic Multi-domain Alzheimer's Risk Reduction Trial". The primary goal of this randomized controlled trial (RCT) is to pilot-test a personalized, pragmatic, multi-domain Alzheimer's disease risk reduction intervention in a U.S. integrated healthcare delivery system.
What is the current status of trial NCT03683394?
This trial is currently completed. It is a NA study. The enrollment target is 172 participants. The study started on 2018-08-30. Estimated completion is 2022-08-10.
What interventions are being tested in trial NCT03683394?
The interventions under investigation include: Health Education Intervention (BEHAVIORAL), SMARRT Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT03683394?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03683394's enrollment target sits among peer trials
172 612th of 2000 higher than 1,389 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI